Related Experiment Videos
External validation of the Melbourne ASSET score for pediatric cellulitis
Céline Thémelin1, Soha Rached Dastous1,2, Brandon Noyon3
1Department of Pediatric Emergency Medicine, Centre Hospitalier Universitaire Sainte Justine, Université de Montréal, Montreal, QC, Canada.
Insights
The Melbourne ASSET Score showed limited ability to predict intravenous antibiotic needs in pediatric cellulitis. It is best used for risk stratification, not as a strict rule for treatment.
Area of Science:
- Pediatric Emergency Medicine
- Infectious Diseases
- Clinical Decision Support Tools
Background:
- Cellulitis is a common pediatric emergency department (ED) presentation.
- Accurate prediction of intravenous (IV) antibiotic therapy need is crucial for effective management.
- The Melbourne ASSET Score was developed to aid this prediction.
Purpose of the Study:
- To conduct the first external validation of the Melbourne ASSET Score.
- To assess the score's accuracy in predicting IV antibiotic therapy for pediatric ED cellulitis.
- To evaluate the score's performance in a Canadian tertiary pediatric ED setting.
Main Methods:
- Prospective cohort study of children aged 6 months to 18 years with cellulitis.
- Exclusion criteria included orbital cellulitis, immunocompromise, clinical toxicity, and inability to tolerate oral antibiotics.
- Primary outcome: IV vs. oral antibiotic administration at 24 hours; secondary outcomes: interrater reliability and treatment failure.
Main Results:
- The ASSET Score had limited discrimination (AUC 0.68) for predicting IV antibiotic use.
- Sensitivity was 74% and specificity was 55% for IV antibiotic use.
- Notably, 57% of children with scores ≥4 were successfully treated with oral antibiotics, and treatment failure was 12%.
Conclusions:
- The Melbourne ASSET Score demonstrated limited discriminative performance for binary IV antibiotic decisions.
- The score is influenced by successful high-dose oral antibiotic pathways.
- It is best used as a risk-stratification tool alongside clinical judgment, not a strict mandate for IV therapy.
Objective:
To perform the first external validation of the Melbourne ASSET Score for predicting the need for intravenous (IV) antibiotic therapy in pediatric emergency department (ED) cellulitis.
Methods:
This prospective cohort study (January 2022-January 2024) at a Canadian tertiary pediatric ED enrolled children aged 6 months to 18 years with cellulitis. Exclusion criteria included orbital cellulitis, immunocompromised state, clinical toxicity, and inability to tolerate oral antibiotics. The primary outcome was IV versus oral antibiotic administration at 24 h. Secondary outcomes included interrater reliability and treatment failure.
Results:
Among 229 children (median age, 5.7 years; 38% female), 54% had an ASSET Score ≥ 4. At 24 h, 69% received oral antibiotics and 31% IV antibiotics. The ASSET Score demonstrated limited discrimination (AUC 0.68; 95% CI 0.61-0.75) and correctly classified 61% of cases. Sensitivity for predicting IV antibiotic use was 74% (95% CI 62-83), specificity 55% (95% CI 47-63), positive predictive value 43% (95% CI 34 52), and negative predictive value 82% (95% CI 73-89). Interrater reliability was substantial (κ = 0.66; 95% CI 0.38-0.95), with variability across individual components. Notably, 57% of children with scores ≥ 4 were successfully managed with oral antibiotics. Treatment failure occurred in 28 patients (12%), with severe complications occurring rarely and exclusively in patients already receiving IV therapy.
Conclusions:
In its first external validation, the Melbourne ASSET Score showed limited discriminative performance as a binary decision rule for IV antibiotics, heavily influenced by successful local high-dose oral therapy pathways. It is best utilized as a risk-stratification tool alongside clinical judgment rather than a strict mandate for IV therapy.
